C1R-sB7 (ATCC® CRL-2370)

Organism: Homo sapiens, human  /  Cell Type: B lymphoblast; Epstein-Barr virus (EBV) transformed  /  Tissue: peripheral blood  / 

Organism Homo sapiens, human
Tissue peripheral blood
Cell Type B lymphoblast; Epstein-Barr virus (EBV) transformed
Product Format frozen
Morphology lymphoblast
Culture Properties mixed; semi-attached
Biosafety Level 2 [Cells contain Herpesvirus]
Storage Conditions liquid nitrogen vapor phase
Derivation

C1R-sB7 is a stable transfectant cell line established in 1988 with a modified histocompatibility complex (MHC) HLA B7 gene. It secretes HLA B7 but does not express surface HLA B7.

C1R-sB7 was established by transfection by electroporation of the C1R cell line with a modified neomycin drug-resistant eukaryotic vector, pSP65-Neo carrying the gene for soluble B7 (sB7). It was selected in geneticin and cloned by limiting dilution. 

C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy.2 B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement.

Genes Expressed
Secretes HLA B7 but does not express surface HLA B7
Comments
C1R-sB7 secretes HLA B7 but does not express surface HLA B7.

C1R-sB7 has been a reference standard in International Workshops on soluble HLA.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Cultures can be maintained by transferring floating cells to additional flasks.
Attached cells may be subcultured by scraping.
Medium Renewal: Every 2 to 3 days
Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37°C
STR Profile
Amelogenin: X
CSF1PO: 6,10
D13S317: 11,13
D16S539: 9,13
D5S818: 10,13
D7S820: 7,12
THO1: 8
TPOX: 8
vWA: 17
Name of Depositor F Grumet
Year of Origin 1988
References

Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569

Grumet FC, et al. Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization. Hum. Immunol. 40: 228-234, 1994. PubMed: 7960967

Hiraki DD, et al. Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization. Hum. Immunol. 40: 235-246, 1994. PubMed: 7960968

Grumet FC, et al. Report of the second international soluble HLA (sHLA) workshop. Phoenix, Arizona, October 2, 1993. Hum. Immunol. 40: 153-165, 1994. PubMed: 7960956

Basic Documentation
References

Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569

Grumet FC, et al. Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization. Hum. Immunol. 40: 228-234, 1994. PubMed: 7960967

Hiraki DD, et al. Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization. Hum. Immunol. 40: 235-246, 1994. PubMed: 7960968

Grumet FC, et al. Report of the second international soluble HLA (sHLA) workshop. Phoenix, Arizona, October 2, 1993. Hum. Immunol. 40: 153-165, 1994. PubMed: 7960956